Advertisement
Canada markets open in 4 hours 42 minutes
  • S&P/TSX

    21,947.41
    +124.21 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +449.98 (+1.18%)
     
  • CAD/USD

    0.7310
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    79.01
    +0.90 (+1.15%)
     
  • Bitcoin CAD

    89,465.15
    +2,226.00 (+2.55%)
     
  • CMC Crypto 200

    1,409.37
    +96.75 (+7.37%)
     
  • GOLD FUTURES

    2,327.70
    +19.10 (+0.83%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ futures

    18,032.00
    +31.25 (+0.17%)
     
  • VOLATILITY

    13.96
    +0.47 (+3.48%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6786
    -0.0001 (-0.01%)
     

Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares

Tyra Biosciences Inc (NASDAQ:TYRA), a company focused on developing precision medicine for patients with cancer, has reported an insider sell according to a recent SEC filing. Daniel Bensen, the Chief Operating Officer of Tyra Biosciences Inc, sold 9,152 shares of the company on March 5, 2024. The transaction was disclosed in an SEC Filing.Over the past year, the insider, Daniel Bensen, has sold a total of 274,297 shares and has not made any purchases of the company's stock. The recent sell by the insider is part of a trend observed over the past year, where there have been no insider buys and 22 insider sells for Tyra Biosciences Inc.

Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares
Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares

On the day of the insider's recent sell, shares of Tyra Biosciences Inc were trading at $20.06. The company currently holds a market cap of $1.016 billion.For more information on insider trades and the financial performance of Tyra Biosciences Inc (NASDAQ:TYRA), investors and shareholders are encouraged to review the full details of the SEC filing and follow the company's updates.

ADVERTISEMENT

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.